Orchestra BioMed Holdings, Inc. announced a public offering of 15 million shares at $5.00 each, raising approximately $75 million before expenses. The proceeds will support pivotal clinical trials for their AVIM Therapy targeting hypertension and the Virtue SAB program for coronary artery disease. These therapies have FDA Breakthrough Device Designations and are in advanced trial stages. The offering is expected to close on November 9, 2026, with Piper Sandler and TD Cowen managing the deal.
Orchestra BioMed's public offering is the subject, with Pluang's health sector market data providing context. For readers following health stocks, 18 of 150 US health-sector stocks rose while 132 fell. Notable movers include ClearPoint Neuro Inc at USD 8.87 with a -12.70% change, Halozyme Therapeutics Inc at USD 114.40 with a -12.23% change, and Nuwellis Inc at USD 4.63 with a -12.14% change. This data is as of Nov 06, 2026 09:22 WIB.
The 2026 Global Health Congress in New York gathered over 625 healthcare leaders from 25 countries to discuss innovation, equity, and investment in healthcare. The event featured 350+ startup applications in its Healthcare Shark Tank competition, cro...
Ambarella, an edge AI semiconductor company, announced its third quarter fiscal year 2027 earnings conference call will be held on November 24, 2026, at 1:30 p.m. Pacific Time. The company will release its earnings report after the market closes that...
TRON founder Sun Yuchen has intensified his legal battle against World Liberty Financial (WLFI) over about 595 million WLFI tokens frozen since September 2025, worth roughly $107 million at the time. The dispute centers on whether the federal court h...
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
